Cord Blood Stem Cell Act of 2005

S.23 Healthy Mothers and Healthy Babies Access,S.338/H.R.985 Bipartisan Medicaid Commission S.354/H.R.534 Medicaid Liability Reform,S.473/H.R.215 Allied Health Professions Reinvestment Act of 2005 Act S.544 Patient Safety and Quality Improvement Act of 2005,S.681 Umbilical Cord Blood Stem Cell Research S.898/H.R.1812 Patient Navigator Outreach & Chronic Disease Prevention Act of 2005 S.1049 Covering Kids Act of 2005,S.1262/H.R.2234 Health Technology to Enhance Quality Act of 2005 & the 21st Century Health Information Act,S.1355 & S.1262 Better Healthcare Through Information Technology Act S.1356/H.R.3617 Medicare Value Purchasing Act of 2005,S.1418 Wired for Health Care Quality Act S.1784 National Medical Error Disclosure & Compensation Act of 2005, S.1955 Health Insurance Marketplace Modernization & Affordability Act of 2005 S.3042 All-Hazards Public Health Emergency and Bioterrorism Preparedness and Response Act H.R.534 Rural Health Equity Act,H.R.880 Rural Health Equity Act,H.R.3173 Nurse Faculty Higher Education Act H.R.3373/S.1405 Preserving Patient Access to Inpatient Rehabilitation Hospitals Act H.R.3607 The Future of Health Care-Granting Access to Innovation in America Act H.R.4157 Health Information Technology Promotion Act of 2005/Hospital Pricing Transparency H.R.5647/S.3708 Labor-Health and Human Services Education Bill FFY 2007 Budget and Budget Resolutions 2007 Medicare Inpatient Hospital PPS Rules 2007 Medicare Inpatient Psychiatric Facility PPS Rules 2007 Medicare Inpatient Rehabilitation Facility PPS and “75% Rule”, Rules 2007 Medicare Outpatient PPS Rules 2007 Medicare Skilled Nursing Facility PPS Rules 2007 Medicare Home Health Agency PPS Rules 2007 Medicare Physician Fee Schedule Update “Stark” and physician self-referral regulations Hospital pricing transparency Not-for-profit hospital tax-exempt status Medicaid regulations affecting states’ Medicaid financing mechanisms Pay for Performance Health information technology Hospital charity care/financial aid Coverage for undocumented immigrants Associated health plans Coverage for the uninsured Health savings accounts and high-deductible health plans Emergency preparedness Immigration S.4 Health Technology to Enhance Quality Act of 2005 S.22 Medical Care Access Protection Act of 2006

Client expense: $20,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE

H.R. 3144 Respect for Life Pluripotent Stem Cell Act of 2005. H.R. 162 Stem Cell Replenishment Act of 2005. H.R. 2574 Respect for Life Embryonic Stem Cell Act of 2005. H.R. 596 Cord Blood Stem Cell Act of 2005. S. 681 Cord Blood Stem Cell Act of 2005. H.R. 810 Stem Cell Research Enhancement Act of 2005.H. CON. RES. 166 Expressing the sense of the Congress that the Federal Government should not infringe on State or private programs that fund embryonic stem cell research. H.R. 1650 Stem Cell Research Investment Act of 2005. H.R. 2541 Joe Testaverde Adult Stem Cell Research Act of 2005. H.R. 2525 Stem Cell Therapeutic and Research Act of 2005. S. 876 Human Cloning Ban and Stem Cell Research Protection Act of 2005. H.R. 1822 Human Cloning Ban and Stem Cell Research Protection Act of 2005.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 16: A bill to reduce to the cost of quality health care coverage and improve the availability of health care coverage for all Americans. Lobbied to protect the interests of the Biotech drug industry. S. 109, H.R. 328: A bill entitled the "Pharmaceutical Market Access Act of 2005". Lobbied for an exemption for biologics.S.184,H.R. 753: A bill to amend the Federal Food, Drug, and Cosmetic Act to protect the public health from the unsafe importation of prescription drugs and from counterfeit prescription drugs, and for other purposes. Lobbied for an exemption for biologics. S. 334, H.R. 700: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 563: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate and disclose lowest possible prices for prescription drug prices for Medicare beneficiaries, and with respect to the Federal Food, Drug, and Cosmetic Act, to provide waivers that permit such beneficiaries to import prescription drugs from Canada. Lobbied for an exemption for biologics. H.R. 578: To amend the Internal Revenue Code of 1986 with respect to the purchase of prescription drugs by individuals who have attained retirement age, and to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs and the sale of such drugs through Internet sites. Lobbied for an exemption for biologics. H.R.1626: To amend part D of the title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negptiate for lower prices for Medicare prescription drugs and to eliminate the gap in coverage of Medicare prescrition durg benefits, to the Secretary of Health and Human Services to promulgate regulations for the reimportation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 2599: To improve the quality, availability, diversity, personal privacy, and innovation of health care in the United States. Lobbied for an exemption for biologics.. H.R.16: To authorize the use of Federal funds for research on human embryonic stem cells irrrespective of the date on which such stem cells were derived, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 596, S. 681: To amend the Public Health Service Act to establish a National Cord Blood Stem Cell Bank Network to prepare, store, and distribute human umbilical cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 810, S. 471: To amend the Public Health Service Act to provide for human embryonic stem cell research. H.R.1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied to prevent the unreasonable restriciton of legitimate medical research or clinical trials. H.R. 1822, S. 876: To prohibit human cloning and protect stem cells research. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2541: To amend the Public Health Service Act to provide for the expansion, intensification, and coordination of the activities of the National Institutes of Health regarding qualifying adult stem cell research, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R.2520, S.1317: To provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to authorize the C.W. Bill Young Cell Transplantation Program. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2574: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.1392: A bill to reauthorize the Federal Trade Commission. (Dorgan/Snowe Drug Importation Amendment). Lobbied for an exemption for biologics. H.R.3144: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research in the derivation and use of human pluripotent stem cells by means that do not harm human embryos, and for other purposes. Lobbied for the interests of the vaccine industry. H.R.3423,S.1420: To amend the Federal Food, Drug, and Cosmetic Act with respect to medical device user fees. Lobbied for the interests of the medical device industry. S.226: A bill to amend the Public Health Service Act to improve immunization rates by increasing the supply of vaccines. Lobbied for the interst of the vaccine industry. S.521,H.R.1290: A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive prevention, research, and medical management referral program for hepatitis C virus infection. Supported bill. S.969,H.R.3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry. S.1422,H.R.881: A bill to amend the Federal Food, Drug, and Cosmetic Act to reduce human exposure to mercury through vaccines. Lobbied for the interests of the vaccine industry. H.R.650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry. H.R.1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restricition of legitimate medical research or clinical trials. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to provide the best information to the patient. H.R.2090: To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. Lobbied for provisions that promoted the development safe and effective drugs. H.R.2124,H.R.2308: To amend the Public Health Service Act to provide for clinical research support grants, clinical research infrastructure grants, and a demonstration program on partnerships in clinical research, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. H.R.2650: To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to protect consumers in managed care plans and other health coverage. Lobbied for the interests of the industry. H.R.2792: To permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests, and for other purposes. Lobbied for the interests of the industry. H.R.3196,H.R.2259,S.1012: To amend the Public Health Service Act to expand the scope of information required for the data bank on clinical trials of drugs, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. S.1128: A bill to amend title XIX of the Social Security Act to provide for increased rebates under the medicaid program for prescription drugs that are directly advertised to consumers, to require other Federal programs purchasing or reimbursing for such drugs to establish payment and reimbursement mechanisms that reduce the costs of those drugs, and for other purposes. Lobbied to ensure that any enacted restrictions would not impede access of the consumer to accurate information about pharmaceutical products. H.R.840,S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.1808,S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.4395: To amend titles XVIII and XIX of the Social Security Act to provide for an improved voluntary Medicare prescription drug benefit, to provide greater access to affordable pharmaceuticals, and for other purposes. Lobbied for an exemption for biologics in the Drug Importation section. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restricition of legitimate medical research or clinical trials. S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R.2345: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. Lobbied in support of enhanced FDA authorities over counterfeit products. H.R.3052,S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry. H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry. S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness. S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply. S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions. General matters related to vaccine industry stability, pandemic preparedness, avian influenza.

FFY2005 Budget Resolution and Appropriation Bills FFY2006 Budget Resolution and Appropriation Bills S.1932 Deficit Reduction Omnibus Reconciliation Act of 2005 2006 Budget reconciliation bill H.R.5/H.R.534/S.354 S.338/H.R.985 Bipartisan Medicaid Commission S.933/H.R.2350 Rural Community Hospital Assistance Act S.1356/H.R.3617 Medicare Value Purchasing Act of 2005 S.1784 National Medical Error Disclosure and Compensation Act of 2005 H.R.3607 The future of Health Care-Granting Access to Innovation in America Act H.R.880 Rural Health Equity Act S.473/H.R.215 Allied Health Professions Reinvestment Act S.898/H.R.1812 Patient navigator Outreach & Chronic Disease Prevention Act of 2005 H.R.139 Health Improvement and Professions Act of 2005 H.R.3173 Nurse Faculty Higher Education Act s.1262/H.R.2234 Health Technology to Enhance Quality Act of 2005 and The 21sst Century Health Information Act S.1355 and S.1262 the Better Healthcare Through Information Technology Act S.1049 Covering Kids Act of 2005 S.681 Umbilical Cord Blood Stem Cell Research S.544/H.R.3205 Patient Safety and quality Improvement Act of 2005 S.4 Health Technology to Enhance Quality Act of 2005 H.R.3373/S.1405 Preserving Patient Access to Inpatient Rehabilitation Hospitals Act Proposed Rules for Medicare Inpatient Psychiatric Facility Payment System (IPF PPS) Visa quota delays Proposed revisiosn to certification requirements for ERSD facilities and OPOs Proposed rule changes for hospital conditions of participation Final Medicare Inpatient PPS rule for FFY2006 Final Outpatient PPS rule for FFY2006 CMS data validation process rules Proposed Medicare inpatient rehabilitation facility (IRF) and skilled nursing facility (SNF) PPS rules for FFY2006 Proposed Post-acute transfer policy Proposed rate update for Medicare Home Health Agency (HHA) PPS Propsoed e-prescribing and electronic health records regulations Mental health parity law extension

S 681 Cord Blood Stem Cell Act of 2005 National cord blood stem cell bank to store stem cells for treatment and research

Client expense: $60,000 · Firm income: Not reported